Recursion’s $200M offering; Sanofi invests $40M in Vigil Neuroscience

Bio­Marin laid out a new cor­po­rate strat­e­gy on Wednes­day, fol­low­ing months of re­or­ga­ni­za­tion and mul­ti­ple staff re­duc­tions. The new struc­ture re­lies on three key busi­ness

Dozens of pathologists who were told they failed their specialty’s board exam over the past 2 years have been alerted that they actually passed. On